Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Outcomes of CPX-352 vs. 7+3 for t-AML

Jeffrey Lancet • 7 Dec 2019
ASH 2019
Acute Myeloid Leukemia Leukemia CPX-351 Cytarabine Daunorubicin

Jeffrey Lancet, MD, Moffitt Cancer Center, Tampa, FL, discusses the exploratory analysis of a phase 3 study performed to compare outcomes in patients with therapy-related acute myeloid leukemia (t-AML) who achieved remission with CPX-351 (daunorubicin and cytarabine in a liposomal formulation for injection) vs 7+3 chemotherapy (NCT01696084). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Jeffrey Lancet

4:48
Canakinumab with darbepoetin in patients with LR-MDS who are ESA-refractory
Jeffrey Lancet • 8 Dec 2023
5:17
COVALENT-101: investigating menin inhibition with BMF-219 for treating patients with R/R AML or ALL
Jeffrey Lancet • 8 Dec 2023
1:45
The impact of secondary-type mutations in NPM1-mutated AML
Jeffrey Lancet • 11 Dec 2021
6:57
Responses to COVID-19 vaccines in patients with AML and MDS
Jeffrey Lancet • 11 Dec 2021

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals